Chad W. Souvignier

RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona.

Jenrin Discovery, Inc. develops therapeutics for chronic diseases. It provides therapeutics for various diseases, including obesity, diabetes, and autoimmune and inflammatory disorders. The company was founded by John F. McLeroy on April 17, 2007 and is headquartered in Philadelphia, PA.

Research Corporation Technologies, Inc. provides investment related services. It operates as technology development company that typically invests in new technology platforms in life sciences, healthcare technology, biomedical, preclinical and clinical-stage therapeutics, devices, drugs, and diagnostics, medical devices, and biotech tools for gene expression and protein production with medical devices. The company was founded in 1987 and is headquartered in Tucson, AZ.

Biolog, Inc. enages in the manufacture of diagnostic substances. It offers microbial identification, phenotype microarrays for microbial and mammalian cells, mitochondria function assays, educational porta, microbiome, microbial community analysis, and microbial detection. The company was founded by Barry R. Bochner and Donald W. Barnby in 1984 and is headquartered in Hayward, CA.

Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury

Esperance Pharmaceuticals, Inc. develops oncology products. It specializes in oncology products that selectively kill cancer cells without harming normal cells. The company was founded by Hector W. Alila in 2006 and is headquartered in Baton Rouge, LA.

Calosyn Pharma, Inc. develops intra-articular therapeutics for osteoarthritis. Its product is based on a class of drugs known as calcium channel blockers. The firm's drugs is used in humans for the treatment of heart and vascular diseases. The company was founded by David D. Waddell and is headquartered in Atlanta, GA.

Aeson Therapeutics, Inc. develops fluasterone as a treatment for lipid disorders, inflammatory diseases and as a cancer chemoprevention agent. The company was founded in 1995 and is headquartered in Tucson, AZ.